The Saudi Food and Drug Authority (SFDA) approved the registration of Frehemgo (denecimig) for routine bleeding prophylaxis in hemophilia A patients, becoming the first global regulator to clear the drug, according to an announcement reported by the Saudi Gazette and PressBee.
Global Regulatory Milestone for Hemophilia A Treatment
The Saudi Food and Drug Authority granted approval for Frehemgo (denecimig), marking the first time a regulatory body worldwide has cleared the treatment. According to reporting from the Saudi Gazette and PressBee, the drug is indicated for the routine prophylaxis of bleeding episodes in patients suffering from hemophilia A, regardless of whether they have factor VIII (FVIII) inhibitors.
Hemophilia A is an inherited bleeding disorder. Patients lack or have a deficiency of FVIII, a vital protein needed for normal blood clotting. This deficit leaves individuals at a much higher risk of experiencing recurrent bleeding episodes, according to the verified source data.
Breakthrough Designation and Mechanism of Action
Prior to receiving full registration, Frehemgo secured a designation under the SFDA’s Breakthrough Medicine Program. According to the Saudi Gazette and PressBee, this program aims to speed up patient access to specialized medical treatments within Saudi Arabia.
Frehemgo functions as a bispecific antibody. It mimics activated FVIII by bridging coagulation factor IXa (FIXa) and factor X (FX) directly on the surface of activated platelets. This process promotes thrombin generation and enhances overall coagulation to stop bleeding. The mechanism works independently of FVIII inhibitors. Patients receive the drug via subcutaneous injection. Dosing frequency ranges from once weekly to every two weeks or once monthly, based on body weight and a physician’s evaluation, according to the source reports.
Clinical Trial Evidence and Safety Data
The regulatory clearance followed a thorough evaluation of efficacy, safety, and quality based on evidence submitted in the registration dossier, as stated by the SFDA. The clinical data evaluated denecimig across four separate Phase 3 studies covering various patient groups, including adults, adolescents, and pediatric patients with all severities of hemophilia A. The trials also included an open-label extension study and a safety-only study examining switches from emicizumab in adults and adolescents.
Clinical studies identified common adverse reactions. These included injection-site reactions like erythema and pruritus, along with pyrexia, headache, and upper respiratory tract infections. Evaluators also noted elevated levels of laboratory markers for coagulation activation, including D-dimer and prothrombin fragment 1+2, according to the Saudi Gazette and PressBee.
Did You Know?
Frehemgo’s mechanism bridges factor IXa and factor X on activated platelets, bypassing the traditional requirement for factor VIII to promote successful blood clotting in hemophilia A patients.
Frequently Asked Questions
What is Frehemgo (denecimig)?
Frehemgo is a bispecific antibody designed for the routine prophylaxis of bleeding episodes in hemophilia A patients, with or without FVIII inhibitors, according to the Saudi Gazette and PressBee.
How is Frehemgo administered?
The medication is given via subcutaneous injection. Dosing occurs once weekly, every two weeks, or once monthly, depending on patient body weight and medical assessment.
Which regulatory body approved Frehemgo first?
The Saudi Food and Drug Authority (SFDA) is the first regulatory body globally to approve the registration of the drug, according to source reports.
Stay Updated on Medical Innovations
Explore our latest coverage on global health regulations and pharmaceutical breakthroughs. Share your thoughts in the comments below or subscribe for updates.
Worth a look